source
- Safety concerns rise as Neurocrine's Prader-Willi drug linked to deaths and hospitalizationsPatient advocates and several experts are voicing increasing alarm over the safety profile of Neurocrine Biosciences' therapy for Prader-Willi syndrome. The drug, Vykat XR, received approval 18 mo…
- Stakeholders urge FDA to adopt flexible approach for psychedelic drug regulationVarious individuals and groups have submitted comments urging the U.S. Food and Drug Administration to be flexible in regulating psychedelic medicines that could treat major depressive disorder and…